Patents-Review.com
ClassID:

20941 ⎘

A61K38/1783 - CPC Classification

Classification description:

Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors

Recent Application in this class:
#1
20250222135
2025-07-10

ADENO-ASSOCIATED VIRUS VECTORS FOR NUCLEIC ACID DELIVERY ACROSS RETINAL REGIONS

 #2
20250213722
2025-07-03

ADENO-ASSOCIATED VIRUS VECTORS FOR NUCLEIC ACID DELIVERY TO RETINAL GANGLION CELLS AND/OR RETINAL PIGMENT EPITHELIUM CELLS

 #3
20240400642
2024-12-05

COMPOSITIONS AND METHODS FOR MODULATING MOLECULES

 #4
20240148830
2024-05-09

Treatment of Neurological Disorder Using NHR

 #5
20230390355
2023-12-07

COMPOSITIONS AND METHODS RELATING TO ALOPECIA

 #6
20220000976
2022-01-06

METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING THE DEVELOPMENT OF FOOD ALLERGIES

 #7
20210361747
2021-11-25

Recombinant thrombomodulin domain 1 for use in treating eye diseases associated with pathological ocular angiogenesis

 #8
20210340218
2021-11-04

MONOCYTE MODULATION AND CONTROL OF TUMOR METASTASIS

 #9
20210315970
2021-10-14

Hepatitis A Virus Replication Inhibitor Targeting mTOR

 #10
20210162007
2021-06-03

MODULATING NUCLEAR RECEPTORS AND METHODS OF USING SAME

 #11
20180312568
2018-11-01

Monocyte modulation and control of tumor metastasis

 #12
20180271941
2018-09-27

Methods for modulating development and function of photoreceptor cells

 #13
20170354688
2017-12-14

Therapeutic effects of NURR1 and FOXA2 in inflammatory neurologic disorders by M1-to-M2 polarization of glial cells

 #14
20160015783
2016-01-21

Methods for modulating development and function of photoreceptor cells

 #15
20160000873
2016-01-07

AGENTS WHICH INDUCE LYMPHANGIOGENESIS FOR USE IN THE TREATMENT OF CYSTIC KIDNEY DISEASE

 #16
20150202261
2015-07-23

Methods and compositions for treating antiprogestin-resistant cancers

 #17
20130108602
2013-05-02

METHODS AND USES OF NUR77 AND NUR77 AGONISTS TO MODULATE MACROPHAGES AND MONOCYTES, AND TREAT INFLAMMATION, INFLAMMATORY DISEASE AND CARDIOVASCULAR DISEASE

 #18
20110229521
2011-09-22

NUTRITIONAL SUPPORT OF THE IMMUNE SYSTEM DURING ANTI-CANCER TREATMENT

 #19
20110229447
2011-09-22

NUTRITIONAL SUPPORT TO PREVENT OR MODERATE BONE MARROW PARALYSIS OR NEUTROPENIA DURING ANTI-CANCER TREATMENT

 #20
20110223136
2011-09-15

Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor

 #21
20100317109
2010-12-16

FACTOR

 #22
20100119505
2010-05-13

Estrogen Related Receptor, ERRalpha, A Regulator of Bone Formation

 #23
20090305980
2009-12-10

Methods and Compositions Related to TR4

 #24
20090087417
2009-04-02

METHODS FOR PROMOTING DOPAMINERGIC NEURONAL DEVELOPMENT BY USING NG4A-SUBFAMILY AND WNT-LIGANDS

 #25
20070196352
2007-08-23

Vegf-induced genes and their therapeutic use

 #26
20070054961
2007-03-08

Factor

 #27
20070054859
2007-03-08

Estrogen receptor-related receptor alpha (ERRalpha) and cartilage formation

 #28
20070031396
2007-02-08

Method of treating neurological diseases

 #29
20060233771
2006-10-19

Methods for promoting dopaminergic neuronal development by using ng4a-subfamily and wnt-ligands

 #30
20060211049
2006-09-21

Estrogen related receptor, ERRα, a regulator of bone formation

 #31
20050070493
2005-03-31

Methods and compositions for treating Parkinson's disease